OCD: Where the serotonin selectivity story begins

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 6, 1996, Pages 11-20

  Pigott, Teresa A ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY NEUROSIS; COMPULSION; DRUG EFFICACY; DRUG SELECTIVITY; HUMAN; MORBIDITY; OBSESSION; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; CLOMIPRAMINE; HUMANS; META-ANALYSIS; OBSESSIVE-COMPULSIVE DISORDER; PLACEBO EFFECT; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0029771645     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:417-422
2. Rasmussen S, Eisen J. Assessment of core features, conviction and psychosocial function in OCD. Presented at the 1st International CCD Conference; March 7-11, 1993; Capri, Italy
3. Foa EB, Kozack MJ. DSM-IV Field Trial: obsessive-compulsive disorder. Am J Psychiatry 1995;152:90-96
4. Rasmussen SA, Eisen JL. Epidemiology and clinical features of obsessive-compulsive disorder. In: Jenike M, Baer L, Minichiello W, eds. Obsessive-Compulsive Disorders: Theory and Management. St. Louis, Mo: Mosby Year Book; 1990:10-27
5. Rasmussen S, Eisen J. The epidemiology and clinical features of obsessive-compulsive disorder. Psychiatr Clin North Am 1992;15:743-758
6. Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive compulsive disorder. J Clin Psychiatry 1992;53(4, suppl):4-10
7. Weissman M, Bland RC, Canino GJ, et al. The cross national epidemiology of obsessive compulsive disorder. J Clin Psychiatry 1994;55(3, suppl): 5-10
8. Karno M, Golding JM, Sorenson SB, et al. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45:1094-1099
9. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990; 47:577-585
10. Greist JH, Jefferson JW, Kobak K, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60
11. Jenike M, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 1989;147;1209-1215
12. Liebowitz MR. The efficacy of antidepressants in anxiety disorders. In: Grinspoon L, ed. Psychiatry Update: The American Psychiatric Association Annual Review. Washington, DC: APA Press: 1984:503-539
13. Murphy DL, Pigott TA. A comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety. J Clin Psychiatry 1990;51(4, suppl):53-58
14. Murphy DL, Pigott TA. Obsessive compulsive disorder and its treatment with serotonin-selective agents. Prog Clin Biol Res 1990;361:179-201
15. Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991;52(6, suppl):4-10
16. WHO Mental Health Collaborating Centres. Pharmacotherapy of depressive disorders: a consensus statement. J Affect Disord 1989;17:197-198
17. Pigott TA, L'Heureux F, Dubbert B, et al. Obsessive compulsive disorder: comorbid conditions. J Clin Psychiatry 1994;55(10, suppl):15-27
18. Barr LC, Goodman WK, Price LH, et al. The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiatry 1992;53(4, suppl):17-28
19. Insel TR, Mueller EA, Alterman I, et al. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry 1985;20:1174-1188
20. Zohar J, Mueller EA, Insel TR, et al. Serotonergic responsivity in obsessive compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry 1987;44:946-951
21. Zohar J, Murphy D, Zohar-Kadouch RC, et al. Serotonin in obsessive-compulsive disorder. In: Coccaro E, Murphy D, eds. Serotonin in Major Psychiatric Disorders. Washington, DC: American Psychiatric Press; 1990: 99-126
22. Altemus M, Pigott T, Kalogeras KT, et al. Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:9-20
23. Asberg M, Thoren P, Bertilsson L. Clomipramine treatment of OCD: biochemical and clinical aspects. Psychopharmacol Bull 1982;18:13-21
24. Lydiard RB, Ballenger JC, Ellinwood EH, et al. CSF monoamine metabolites in obsessive compulsive disorder. In: New Research Program and Abstracts of the 143rd Annual Meeting of the American Psychiatric Association; May 15, 1990; New York, NY. Abstract NR288:156
25. Swedo SE, Leonard HL, Kruesi MJP, et al. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:29-36
26. Thoren P, Asberg M, Bertilsson L, et al. Clomipramine treatment of obsessive-compulsive disorder, II: biochemical aspects. Arch Gen Psychiatry 1980;37:1289-1294
27. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987;22:667-687
28. Yaryura-Tobias JA, Bhagavan HN. L-Tryptophan in obsessive-compulsive disorder. Am J Psychiatry 1977;134:1298-1299
29. 3H]-imipramine binding label serotonin reuptake sites in brain and platelet? Life Sci 1981;28:2753-2760
30. Lingjaerde O. Blood platelets as a model system for studying the biochemistry of depression. In: Usdin E, Asberg M, Bertilsson L, eds. Frontiers in Biochemical and Pharmacological Research in Depression: Advances in Biochemical Psychopharmacology. New York, NY: Raven Press; 1984: 173-182
31. Flament MF, Rapaport JL, Murphy DL, et al. Biochemical changes during Clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 1987;44:219-225
32. Weizman A, Carmi M, Hermesh H, et al. High-affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients. Am J Psychiatry 1986;143:335-339
33. Ravizza L, Maina G, Rocca P, et al. Biological and therapeutic aspects of obsessive compulsive disorder. Presented at the 1st International OCD Conference; March 7-11, 1993; Capri, Italy
34. Marazziti D, Lensi P, Ravagli S, et al. Peripheral nervous system markers in obsessive compulsive disorder. Presented at the 1st International OCD Conference; March 7-11, 1993; Capri, Italy
35. Vitiello B, Shimon H, Behar D, et al. Platelet imipramine binding and serotonin uptake in obsessive-compulsive patients. Acta Psychiatr Scand 1991; 84:29-32
36. Gorman JM, Liebowitz MR, Fyer AJ, et al. Lactate infusions in obsessive-compulsive disorder. Am J Psychiatry 1985;142:864-866
37. Hollander E, Fay M, Cohen B, et al. Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. Am J Psychiatry 1988;145:1015-1018
38. Hollander E, DeCaria C, Nitescu A, et al. Noradrenergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to clonidine and comparison to healthy controls. Psychiatry Res 1991;137: 161-177
39. Pigott TA, L'Heureux F, Bernstein SE, et al. A controlled comparison of clomipramine and m-chlorophenylpiperazine in patients with obsessive compulsive disorder. Presented at the annual meeting of the New Clinical Drug Evaluation Unit; May 26-28, 1992; Key Biscayne, Fla
40. Rasmussen SA, Goodman WK, Woods SW, et al. Effects of yohimbine in obsessive compulsive disorder. Psychopharmacol Bull 1987;93:308-313
41. Charney DS, Goodman WK, Price LH, et al. Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry 1988;45:177-185
42. Pigott TA, Zohar J, Hill JL, et al. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry 1991;29: 418-426
43. Pigott TA, Hill JL, Grady TA, et al. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to IV mCPP. Biol Psychiatry 1993;33:3-14
44. Goodman WK, McDougle CJ, Price LH, et al. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry 1995;38:138-149
45. Hollander E, DeCaria CM, Nitescu A, et al. Serotonergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 1992;49:21-28
46. Charney DS, Woods SW, Goodman WK, et al. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 1987;144:1030-1036
47. Charney DS, Woods SW, Goodman WK, et al. Serotonin function in anxiety, II: effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987;92:14-24
48. Charney DS, Woods SW, Krystal JH, et al. Hypothesis relating serotonergic dysfunction to the etiology and treatment of panic and generalized anxiety disorders. In: Coccaro E, Murphy D, eds. Serotonin in Major Psychiatric Disorders. Washington, DC: American Psychiatric Press; 1990:127-152
49. Kahn RS, Asnis GM, Wetzler S, et al. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology (Berl) 1988;96:360-364
50. Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993;54(8, suppl):3-15
51. Lydiard RB. Coexisting depression and anxiety: special diagnostic and treatment issues. J Clin Psychiatry 1991;52(6, suppl):48-54
52. Sheehan DV, Zak JP, Miller JA Jr, et al. Panic disorder: the potential role of serotonin reuptake inhibitors. J Clin Psychiatry 1988;49(8, suppl):30-36
53. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985;46(3, sec 2):53-58
54. Jenike MA. Pharmacologic treatment of obsessive compulsive disorders. Psychiatr Clin North Am 1992;15:895-919
55. Benfield D, Harris C, Luscombe D. Some psychopharmacological aspects of desmethylclomipramine. Postgrad Med 1980;56:13-18
56. Jenike MA, Baer L, Greist JH. Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. J Clin Psychopharmacol 1990;10:122-124
57. Nierenberg AA, Cole JO. Antidepressant adverse drug reactions. J Clin Psychiatry 1991;52(6, suppl):40-47
58. Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:1543-1550
59. Stern RS, Marks IM, Wright J, et al. Clomipramine: plasma levels, side effects and outcome in obsessive-compulsive neurosis. Postgrad Med J 1980; 56(1, suppl):134-139
60. Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Res 1985;14:85-93
61. Ananth J, Solyom L, Solyom C, et al. Doxepin in the treatment of obsessive compulsive neurosis. Psychosomatics 1975;16:185-187
62. Ananth J, Pecknold JC, van den Steen N, et al. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol 1981;5:257-262
63. Leonard H, Swedo S, Coffey M, et al. Clomipramine vs desipramine in childhood obsessive compulsive disorder. Psychopharmacol Bull 1988;24:43-45
64. Vallejo J, Olivares J, Marcos T, et al. Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. Br J Psychiatry 1992;161:665-670
65. Insel TR, Murphy DL, Cohen RM, et al. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605-612
66. Jain VK, Swinson RP, Thomas JG. Phenelzine in obsessional neurosis. Br J Psychiatry 1970;117:237-238
67. Hermesh H, Aizenberg D, Munitz H. Trazodone treatment in clomipramine-resistant obsessive-compulsive disorder. Clin Neuropharmacol 1990;13:322-328
68. Pigott TA, L'Heureux F, Rubenstein CS, et al. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:156-162
69. Boyer WF, Feighner JP. An overview of paroxetine. J Clin Psychiatry 1992; 53(2, suppl):3-6
70. DeVane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992;53(2, suppl):13-20
71. Richelson E. Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-1081
72. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-738
73. Tollefson GD, Rampey AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-567
74. Chouinard G, Goodman W, Greist J, et al. Results of a double-blind placebo-controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1990; 26:279-284
75. Greist J, Chouinard G, Duboff E, et al. Long-term sertraline treatment of obsessive compulsive disorder. Presented at the annual meeting of the American College of Neuropsychopharmacology; Dec. 12-15, 1989; San Juan, Puerto Rico
76. Greist J, Chouinard G, DuBoff E, et al. Double-blind comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-295
77. Wheadon D, Bushnell W, Steiner M. A fixed-dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive compulsive disorder. Presented at the annual meeting of the American College of Neuropsychopharmacology; Dec. 10-13, 1993; San Juan, Puerto Rico
78. Rasmussen S, Goodman W, Greist J, et al. Fluvoxamine in the treatment of obsessive compulsive disorder: a multi-center double-blind, placebo-controlled study in outpatients. Am J Psychiatry. In press
79. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
80. Freeman CPL, Trimble MR, Deakin JFW, et al. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;55:301-305
81. Bisserbe J-C, Wiseman R, Goldberg MS, et al. A double-blind comparison of sertraline and clomipramine in outpatients with OCD. In: New Research Program and Abstracts of the Annual Meeting of the American Psychiatric Association; May 24, 1995; Miami, Fla. Abstract NR439:173
82. Pato MT, Pigott TA, Hill JL, et al. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991; 148:127-129
83. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:53-60
84. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-295
85. Greist JH, Jefferson JW, Kobak KA, et al. A 1-year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995;10:57-65
86. Pigott T, L'Heureux F, Murphy D. Pharmacological approaches to treatment-resistant obsessive compulsive disorder patients. Presented at the 1st International OCD Conference; March 7-11, 1993; Capri, Italy
87. Mavissakalian M, Jones B, Olsen S, et al. Absence of placebo response in obsessive compulsive disorder. J Nerv Ment Dis 1990;178:268-270
88. Baer L. Factor analysis of symptom subtypes of obsessive compulsive disorder and their relation to personality and tic disorders. J Clin Psychiatry 1994;55(3, suppl):18-23
89. Goodman WK, McDougle CJ, Price LH, et al. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 1990;51(8, suppl):36-43
90. Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies. J Clin Psychiatry 1994;55 (3, suppl):11-17
91. McDougle CJ, Goodman WK, Price LH. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry 1994;55(3, suppl):24-31